JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265420

Human TXNDC9 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

TXNDC9 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2.

View Alternative Names

APACD, ATP-binding protein associated with cell differentiation, ES cell related protein, PHLP3, Phosducin like protein 3, Protein 1-4, TXND9_HUMAN, TXNDC9 protein, Thioredoxin domain containing 9, Thioredoxin domain-containing protein 9

4 Images
Western blot - Human TXNDC9 knockout HeLa cell line (AB265420)
  • WB

Lab

Western blot - Human TXNDC9 knockout HeLa cell line (AB265420)

Lanes 1-3 : Merged signal (red and green). Green - ab185959 observed at 27 kDa. Red - loading control ab8245 observed at 36 kDa.

ab185959 Anti-TXNDC9 antibody [EPR15238] was shown to specifically react with TXNDC9 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab265420 (knockout cell lysate ab258257) was used. Wild-type and TXNDC9 knockout samples were subjected to SDS-PAGE. ab185959 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated at room temperature for 2. 5 hours at 1 in 1000 dilution and 1 in 20000 dilution respectively.Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-TXNDC9 antibody [EPR15238] (<a href='/en-us/products/primary-antibodies/txndc9-antibody-epr15238-ab185959'>ab185959</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

TXNDC9 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human TXNDC9 knockout HeLa cell line (ab265420)

Lane 3:

K-562 cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/10000 dilution

Predicted band size: 27 kDa

Observed band size: 27 kDa

false

Western blot - Human TXNDC9 knockout HeLa cell line (AB265420)
  • WB

Lab

Western blot - Human TXNDC9 knockout HeLa cell line (AB265420)

Lanes 1-3 : Merged signal (red and green). Green - ab191405 observed at 27 kDa. Red - loading control ab8245 observed at 36 kDa.

ab191405 Anti-TXNDC9 antibody [EPR15239] was shown to specifically react with TXNDC9 in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab265420 (knockout cell lysate ab258257) was used. Wild-type and TXNDC9 knockout samples were subjected to SDS-PAGE. ab191405 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated at room temperature for 2. 5 hours at 1 in 1000 dilution and 1 in 20000 dilution respectively.Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

All lanes:

Western blot - Anti-TXNDC9 antibody [EPR15239] (<a href='/en-us/products/primary-antibodies/txndc9-antibody-epr15239-ab191405'>ab191405</a>) at 1/1000 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

TXNDC9 knockout HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human TXNDC9 knockout HeLa cell line (ab265420)

Lane 3:

K-562 cell lysate at 20 µg

Secondary

All lanes:

Western blot - Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-irdye-800cw-preadsorbed-ab216773'>ab216773</a>) at 1/10000 dilution

Predicted band size: 27 kDa

Observed band size: 27 kDa

false

Sanger Sequencing - Human TXNDC9 knockout HeLa cell line (AB265420)
  • Sanger seq

Unknown

Sanger Sequencing - Human TXNDC9 knockout HeLa cell line (AB265420)

Allele-2 : 1 bp insertion in exon 2.

Sanger Sequencing - Human TXNDC9 knockout HeLa cell line (AB265420)
  • Sanger seq

Unknown

Sanger Sequencing - Human TXNDC9 knockout HeLa cell line (AB265420)

Allele-1 : 1 bp deletion in exon 2.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 1 bp insertion in exon 2

Disease

Adenocarcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265420-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265420 Human TXNDC9 knockout HeLa cell line", "number":"AB265420-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265420-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265420 Human TXNDC9 knockout HeLa cell line", "number":"AB265420-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
TXNDC9
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

TXNDC9 also known as Thioredoxin Domain Containing 9 or ERdj5 functions as a protein disulfide isomerase involved in the reduction and isomerization of disulfide bonds. This protein weighs approximately 56 kDa and exhibits expression mostly in the endoplasmic reticulum of various cells. TXNDC9 with its oxidoreductase activity plays an important role in maintaining protein folding homeostasis and cellular redox balance. Researchers have identified it as a central player in protein quality control mechanisms.
Biological function summary

TXNDC9 assists in the protein folding process within the endoplasmic reticulum acting as part of larger protein complexes that include other chaperones. It particularly engages in helping misfolded proteins to attain their correct conformation contributing significantly to the protein folding machinery. Additionally TXNDC9 interacts with client proteins guiding their correct structural organization and preventing the accumulation of misfolded proteins that could be harmful to the cell.

Pathways

TXNDC9 occupies a significant position in the endoplasmic reticulum-associated degradation (ERAD) pathway and the unfolded protein response (UPR) pathway. It interacts with proteins such as Ero1 and BiP to ensure proper degradation of misfolded proteins and maintain cellular stress responses. In the ERAD pathway TXNDC9 acts to identify and prepare proteins for degradation while in the UPR pathway it supports roles that mitigate stress signals caused by accumulated unfolded proteins.

TXNDC9 involvement links to neurodegenerative diseases and certain cancers. Its role in maintaining protein homeostasis reflects connections to Alzheimer's disease where protein misfolding aggregates contribute to pathology. Similarly aberrant TXNDC9 function associates with tumor development in some cancers due to its involvement with cellular redox status and growth control mechanisms. In these contexts TXNDC9 may interact with proteins like Amyloid-beta in Alzheimer's and could influence oncogenic pathways through interactions with tumor-suppressor proteins.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com